22 articles for X Lv
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
Hangzhou Xixi Hospital
Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Hangzhou Xixi Hospital
Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).
Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors.
China Pharmaceutical University
Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses.
Chinese Academy of Sciences
Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues.
Anhui University of Chinese Medicine
Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
Hangzhou Medical College
Synthesis and biological evaluation of new series of benzamide derivatives containing urea moiety as sEH inhibitors.
Shenyang Pharmaceutical University
Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
Jiaxing University
Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
Hefei University of Technology
Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism.
Dalian Medical University
Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.
Hefei University of Technology
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor
Boehringer Ingelheim Rcv
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Agios Pharmaceuticals
Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
Hefei University of Technology
Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation.
Zhejiang University
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Agios Pharmaceuticals
Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts.
Anhui University of Chinese Medicine
The selectivity and bioavailability improvement of novel oral anticoagulants: An overview.
Hefei University of Technology
Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
Hangzhou Xixi Hospital
1-ALKYL-5-ARYLIDENE-2-SELENOXOIMIDAZOLIDINE-4-ON AND DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, AND COMPOSITION COMPRISING SAME FOR PREVENTING, ALLEVIATING OR TREATING NEURODEGENERATIVE DISEASES
Duksung Women''S University Industry-Academic Cooperation Foundation